EDI’s HOT cell culture systems will be combined with RBM’s MAP products.
Rules-Based Medicine (RBM) bought Experimentelle and Diagnostische Immunologie (EDI) thus combining their respective ex vivo biomarker testing platforms. EDI develops human organotypic (HOT) cell culture test systems, which RBM expects to have strong synergies with its multianalyte profiling (MAP) biomarker services.
“Combining RBM’s MAP products and services with EDI’s HOT systems enables us to better serve both our existing and new customers,” notes T. Craig Benson, CEO of RBM. “These solutions will standardize sample collection, cell treatment, and result generation to provide investigators with the most reliable and reproducible approach to therapeutic and consumer product development.”
EDI is based in Reutlingen, Germany, and will operate as a subsidiary of RBM. An EDI product, the instant leukocyte culture system (ILCS®), is designed to replace the peripheral blood mononuclear cell cultures. RBM says that it will couple ILCS with its MAP testing service to provide an understanding of a compound’s effects in the preclinical research phase.